Numerous studies have shown that TAMs are capable of affecting breast cancer cells in a variety of aspects: including tumor growth, metastasis, therapy resistance, and adverse clinicopathological characteristics such as larger tumor size, lymph node metastasis, HR negativity, and HER2 expression [15]. This evidence concerns the gene ERBB2 and breast cancer.